Restylane Refyne, Restylane Defyne
Q-Med AB · Decision date Dec 9, 2016
What did the FDA approve?
The FDA database entry for P140029 records a December 9, 2016 approval for two dermal implants from Q-Med AB. Restylane Refyne is approved for injection into the mid-to-deep dermis to correct moderate to severe facial wrinkles and folds, such as nasolabial folds, in patients over 21. Restylane Defyne carries the same age and injection-depth language but is limited to moderate to severe, deep facial wrinkles and folds.
This entry is an original PMA approval, not a supplement or manufacturing notice. The statement reports the approved indications only; it does not provide independent evidence of safety or clinical effectiveness. No trial data, performance metrics, or comparative outcomes appear in the source fields.
FDA approval order statement
Approval for Restylane Refyne is indicated for injection into the mid-to-deep dermis for the correction of moderate to severe facial wrinkles and folds (such as nasolabial folds) in patients over the age of 21. Restylane Defyne is indicated for injection into the mid-to-deep dermis for the correction of moderate to severe, deep facial wrinkles and folds (such as nasolabial folds) in patients over the age of 21.
- Regulatory pathway
- Original PMA
- Clinical specialty
- General, Plastic Surgery
- Decision date
- Dec 9, 2016
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- P140029
- Regulatory pathway
- Premarket approval application
- Applicant
- Q-Med AB
- Product code
- LMH
- Decision code
- APPR
- Decision date
- Dec 9, 2016
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Implant, dermal, for aesthetic use.
The approval statement above describes the scope recorded for this original decision. Later supplements may change the device or its indications.
FDA decision timeline
P140029 received
Application receipt date recorded by FDA.
P140029 · FDA decision
APPR
P140029/S058 · Related supplement
Restylane Contour
Timeline entries are records held by MedtechLedger for P140029. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P140029
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
Restylane ContourP140029/S058 | Q-Med AB | PMA supplement | Sep 18, 2026 | FDA |
Explore the linked device profile
Other records with product code LMH
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
Juvéderm Ultra XC; Juvéderm Ultra Plus XCP050047/S106 | Allergan | PMA supplement | Nov 4, 2026 | FDA |
Belotero Volume (+) LidocaineP250020/S004 | Merz North America, Inc. | PMA supplement | Nov 4, 2026 | FDA |
Belotero Intense (+) Lidocaine Dermal FillerP250016/S006 | Merz North America, Inc. | PMA supplement | Oct 21, 2026 | FDA |
| Prollenium Medical Technologies, Inc. | PMA supplement | Oct 14, 2026 | FDA | |
saypha ChiQP250021/S002 | Croma-Pharma GmbH | PMA supplement | Oct 8, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
An original PMA is a premarket approval application. The recorded approval scope is described in FDA’s order and supporting documents.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Q-Med AB
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- Seminariegatan 21, Uppsala, S-752 28
Sources and methodology
- Original FDA record: P140029
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records




